Chromatin/Epigenetics
Chromatin/epigenetics inhibitors are compounds that modulate the structure and function of chromatin or interfere with epigenetic modifications, such as DNA methylation and histone modification. These inhibitors are essential tools for studying gene expression regulation and the role of epigenetics in diseases like cancer, neurological disorders, and developmental abnormalities. By targeting epigenetic processes, these inhibitors can alter gene expression patterns and offer new therapeutic avenues. At CymitQuimica, we provide a wide selection of high-quality chromatin/epigenetics inhibitors to support your research in molecular biology, genetics, and epigenetics.
Subcategories of "Chromatin/Epigenetics"
Found 2615 products of "Chromatin/Epigenetics"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
PRMT5-IN-1
CAS:PRMT5-IN-1 is a covalent inhibitor of protein arginine methyltransferase 5 (PRMT5)(IC50 of 11 nM for PRMT5/MEP50).Formula:C19H19ClN4O5Purity:98%Color and Shape:SolidMolecular weight:418.83CBP/p300-IN-18
CBP/p300-IN-18 (compound 8) is a potent inhibitor of EP300/CBP HAT, acting on HAT EP300 (IC50: 0.056 μM) and LK2 H3K27 (IC50: 0.46 μM).Formula:C25H27FN4O3Color and Shape:SolidMolecular weight:450.51K252d
CAS:K252d: indolocarbazole alkaloid in Nocardiopsis; inhibits PKC in rat brain and bovine heart phosphodiesterase.Formula:C26H23N3O5Color and Shape:SolidMolecular weight:457.48LSD1-IN-16
LSD1-IN-16 (4b) inhibits LSD1, MAO-A/B; IC50: 0.015-0.366 μM. Halts prostate cancer cell growth; IC50: 15.2 μM.Formula:C20H18N2OSColor and Shape:SolidMolecular weight:334.43Menin-MLL inhibitor 4
CAS:Menin-MLL inhibitor 4 has antitumor activity.Menin-MLL inhibitor 4 is an inhibitor of Menin- MLL (mixed-lineage leukemia protein) interaction .Formula:C32H38FN7O3Purity:98%Color and Shape:SolidMolecular weight:587.69PARP1-IN-29
CAS:PARP1-IN-29 is an orally active PARP-1 inhibitor with an IC50 of 6.3 nM. When labeled with [18F], PARP1-IN-29 can be utilized for positron emission tomography (PET) imaging, specifically targeting PARP-1 in tumors. This compound is useful in oncology and imaging studies, particularly for detecting PARP-1 activity in cancer.Formula:C18H16FN3O2Color and Shape:SolidMolecular weight:325.34JAK3 covalent inhibitor-1
CAS:JAK3 Covalent Inhibitor-1 is a compound characterized by its potent and selective inhibition of Janus kinase 3 (JAK3), possessing an IC50 of 11 nM andFormula:C22H17FN6O2SPurity:98%Color and Shape:SolidMolecular weight:448.47SMARCA2/4-ligand-5
CAS:SMARCA2/4-ligand-5 is the target protein ligand of PROTAC SMARCA2/4 degrader-37 (Example 4). PROTAC SMARCA2/4 degrader-37 (Example 4) is a PROTAC degrader of SMARCA2/4, with an IC50 value of ≤0.1 μM.Formula:C20H13ClN4O3Color and Shape:SolidMolecular weight:392.795GSK789
CAS:GSK789 is a selective inhibitor of the first bromodomains (BD1) of the bromo and extra terminal domain (BET) proteins.Formula:C26H33N5O3Color and Shape:SolidMolecular weight:463.57BRD-7880
CAS:BRD-7880 is a potent and highly specific inhibitor of aurora kinases B and C.Formula:C32H38N4O7Color and Shape:SolidMolecular weight:590.67TDI-015051
CAS:TDI-015051 is an orally active inhibitor of SARS-CoV-2 non-structural protein 14 (SARS-CoV-2 NSP14) with an IC50 of ≤0.15 nM. It effectively inhibits SARS-CoV-2 NSP14 in Huh-7.5 cells (EC50=11.4 nM) and A549 cells expressing ACE2-TMPRSS2 (EC50=64.7 nM). Additionally, TDI-015051 suppresses other coronaviruses such as α-hCoV-NL63, α-hCoV-229E, and β-hCoV-MERS with IC50 values of 1.7, 2.6, and 3.6 nM, respectively. This compound inhibits viral RNA methylation and replication by binding to a stable SAH-cap pocket and demonstrates anti-infection activity in mouse models.Formula:C22H22FN5O4SColor and Shape:SolidMolecular weight:471.505(Rac)-RG108
CAS:(Rac)-RG108 (NSC401077) is an inhibitor of DNMT1, effectively blocking DNA methyltransferases.Formula:C19H14N2O4Color and Shape:SolidMolecular weight:334.326Dot1L-IN-1
CAS:The Ki value of DOT1L-in-1 is 2pm.It is a highly effective, selective and novel Dot1L inhibitor.Formula:C32H36ClN9O2SPurity:98%Color and Shape:SolidMolecular weight:646.21G-631
CAS:G-631 acts as a selective tankyrase inhibitor, effectively hindering tankyrase auto-PARsylation (poly ADP ribosylation) at an IC 50 of 7 nM and suppressing the Wnt signaling pathway. This compound also demonstrates favorable pharmacokinetic properties in mice.Formula:C19H22F2N6O3Color and Shape:SolidMolecular weight:420.41AJI-214
CAS:AJI-214 functions as a dual-target inhibitor that specifically blocks Aurora kinase A and JAK2. By directly inhibiting Aurora kinase A, AJI-214 prevents mitotic progression and cell polarity in T cells while concurrently suppressing JAK2 activation to reduce STAT3 phosphorylation. This inhibition decreases the differentiation of TH1 and TH17 cells. AJI-214 is utilized in research focused on the modulation of immune responses and the prevention of graft-versus-host disease (GVHD).Formula:C17H13ClFN5OColor and Shape:SolidMolecular weight:357.77BET-IN-8
BET-IN-8 (Compound 27) is a potent inhibitor of BET (Ki: 0.83 μM, Kd: 0.571 μM), which ameliorates LPS-induced sepsis in vivo.BET-IN-8 has shown potential inFormula:C22H21N3O4SColor and Shape:SolidMolecular weight:423.48DS17701585
DS17701585: Oral EP300/CBP inhibitor; potent on CBP, EP300, H3K27, & SOX2; useful for cancer research.Formula:C24H26N4O5SColor and Shape:SolidMolecular weight:482.55BRD4-BD1/2-IN-2
CAS:BRD4-BD1/2-IN-2 inhibits BRD4 BD1/BD2 with IC50 <300 nM/<0.5 nM (WO2021233371A1).Formula:C30H33N5O4Color and Shape:SolidMolecular weight:527.61HDAC2-IN-1
HDAC2-IN-1 is an oral HDAC2 inhibitor (IC50: 0.5 μM), crosses the blood-brain barrier, and inhibits HDAC1 and HDAC8.Formula:C22H23ClN4OSColor and Shape:SolidMolecular weight:426.96HDAC-IN-33
HDAC-IN-33 inhibits HDAC1/2/6 (IC50: 24/46/47 nM), exhibits potent antitumor activity in vitro and in vivo, and activates antitumor immunity.Formula:C21H25N3O3Color and Shape:SolidMolecular weight:367.44PARP10/15-IN-1
PARP10/15-IN-1 (compound 8l) is a dual PARP10 and PARP15 inhibitor with IC50s of 160 nM and 370 nM, respectively. It can be used in cancer research[1].Formula:C13H10N2O3SColor and Shape:SolidMolecular weight:274.3RK-582
CAS:RK-582: oral spiroindolinone tankyrase inhibitor, halts colon cancer growth in COLO-320DM mouse model.Formula:C27H35FN6O3Color and Shape:SolidMolecular weight:510.6HDAC/HSP90-IN-4
HDAC/HSP90-IN-4 inhibits HDAC (20 IC50=194nM, 26 IC50=360nM) & HSP90α (20 IC50=153nM, 26 IC50=77nM), affects cancer cell survival and invasion.Formula:C20H23N3O6Color and Shape:SolidMolecular weight:401.15869AZ0108
CAS:AZ0108, an oral PARP1,2,6 inhibitor, selectively blocks centrosome clustering, is viable for in vivo studies, and doesn't inhibit PARP3/TNKS1.Formula:C24H20F4N6O2Color and Shape:SolidMolecular weight:500.45LSD1/2-IN-3
LSD1/2-IN-3 selectively inhibits LSD1 (Ki 11 nM) over LSD2 (Ki 7 μM), and hinders tumor stem cell proliferation.Formula:C9H8BrF2NColor and Shape:SolidMolecular weight:248.07AZ13824374
AZ13824374: potent, selective ATAD2 inhibitor; anti-proliferative in breast cancer; pIC50: FRET 8.2, NanoBRET 6.2.Formula:C30H39FN8O2Color and Shape:SolidMolecular weight:562.68LSD1-IN-17
LSD1-IN-17, a potent LSD1/CoREST/MAO inhibitor, IC50: 0.005/0.028/0.820 μM; hinders LNCaP prostate cancer cell growth, IC50: 17.2 μM.Formula:C20H18N2OSColor and Shape:SolidMolecular weight:334.43TY-011
CAS:TY-011 is an inhibitor of Aurora A/B kinases. This compound induces DNA damage and cell apoptosis (Apoptosis) in human gastric cancer cells by promoting abnormal microtubule-kinetochore attachments, effectively suppressing cancer cell proliferation. The IC50 values for TY-011 in human gastric cancer cell lines range from 0.11-4.49 μM. It is utilized in research focused on gastric cancer.Formula:C18H16ClN5Color and Shape:SolidMolecular weight:337.81B026
CAS:B026: Oral p300/CBP HAT inhibitor, IC50: p300 1.8 nM, CBP 9.5 nM; targets AR+ prostate cancer cells.Formula:C27H23F4N5O4Color and Shape:SolidMolecular weight:557.5JAK2 JH2 binder-1
CAS:JAK2 JH2 binder-1: potent, selective, Ki=37.1 nM, potential for studying myeloproliferative neoplasms.Formula:C29H25N7O6SColor and Shape:SolidMolecular weight:599.62LSD1-IN-19
LSD1-IN-19 is a potent, selective LSD1 inhibitor with Ki of 0.108 μM and 72h IC50 values of 0.17-0.40 μM.Formula:C33H42N6O2Color and Shape:SolidMolecular weight:554.73KDOAM-25 trihydrochloride
KDOAM-25 trihydrochloride selectively inhibits KDM5 enzymes, boosts H3K4 methylation, and suppresses MM1S cell growth.Formula:C15H28Cl3N5O2Color and Shape:SolidMolecular weight:416.77BRD4 D1-IN-2
BRD4 D1-IN-2 (compound 26), a BRD4 D1 inhibitor, IC50 <0.092 μM, 15 nM affinity, >500x selectivity over BRD2 D1/BRD4 D2.Formula:C33H39F3N6OColor and Shape:SolidMolecular weight:592.7BET-IN-1
BET-IN-1 is a potent inhibitor of BET, exhibiting good brain permeability and a reasonable metabolic stability.Formula:C23H24ClFN4O3SColor and Shape:SolidMolecular weight:490.98PRMT5-IN-1 hydrochloride
PRMT5 IN-1 hydrochloride is a potent PRMT5 inhibitor (IC50: 11 nM), forms covalent adduct with C449, and converts to an aldehyde in vivo.Formula:C19H20Cl2N4O5Color and Shape:SolidMolecular weight:455.29PKCiota-IN-1
CAS:PKCiota-IN-1: Strong PKC-ι inhibitor (IC50=2.7 nM); also blocks PKC-α/ε (IC50s=45/450 nM).Formula:C25H22FN5OColor and Shape:SolidMolecular weight:427.47WDR5-IN-5
CAS:WDR5-IN-5: Selective oral inhibitor for WDR5's WIN site with high affinity (Ki<0.02 nM) and anti-cancer properties. Good pharmacokinetics.Formula:C29H29F3N6OColor and Shape:SolidMolecular weight:534.58Menin-MLL inhibitor 26
CAS:Menin-MLL inhibitor 26: Active reference, inhibits cell growth, used in leukemia research.Formula:C27H29F3N6O3SColor and Shape:SolidMolecular weight:574.62JAK1/TYK2-IN-3
JAK1/TYK2-IN-3, orally active, selectively inhibits TYK2 (IC50: 6 nM), JAK1 (37 nM), JAK2 (140 nM), JAK3 (362 nM), and has anti-inflammatory effects.Color and Shape:SolidPRMT5-IN-21
PRMT5-IN-21 (compound 1) is a potent inhibitor of cyclonucleoside PRMT5.Formula:C18H18F2N6O3Color and Shape:SolidMolecular weight:404.37PARP7-IN-12
CAS:PARP7-IN-12, a potent inhibitor targeting PARP7, exhibits an IC50 of 7.836 nM. This compound is applicable in cancer research.Formula:C23H27ClF3N5O5Color and Shape:SolidMolecular weight:545.94Aurora A inhibitor 1
CAS:Aurora A inhibitor 1: potent, selective, targets cancer-linked Aurora A overexpression, potential for cancer research. (WO2021147974A1, 49)Formula:C25H28ClF2N5O2Color and Shape:SolidMolecular weight:503.97MTL-CEBPA
MTL-CEPBA is a small activating RNA that targets C/EBPα upregulation and exhibits anti-inflammatory and anti-cancer effects.Color and Shape:SolidAurora inhibitor 1
CAS:Aurora inhibitor 1 is a potent Aurora inhibitor (IC50: ≤ 4 nM and ≤13 nM for Aurora A and Aurora B kinase).Formula:C23H25N9SPurity:98%Color and Shape:SolidMolecular weight:459.57EZH2-IN-12
EZH2-IN-12 (Compound 5) is a potent inhibitor of EZH2, which has potential for studies of CNS malignancies.Formula:C23H23Cl2N3O3Color and Shape:SolidMolecular weight:460.35P300 bromodomain-IN-1
P300 bromodomain-IN-1 blocks c-Myc, induces G1/G0 arrest, apoptosis. Potent EP300 inhibitor (IC50: 49 nM).Formula:C29H31ClN4O4Color and Shape:SolidMolecular weight:535.03JAK3-IN-11
CAS:JAK3-IN-11: potent oral JAK3 inhibitor (IC50=1.7 nM), noncytotoxic, >588-fold selectivity, blocks T-cell growth; useful in autoimmune research.Formula:C23H23N5O2Color and Shape:SolidMolecular weight:401.46Sapintoxin D
CAS:Sapintoxin D is a fluorescent phorbol ester and selective activator of protein kinase C.Formula:C30H37NO8Color and Shape:SolidMolecular weight:539.62FNDR-20123
FNDR-20123: First safe, effective anti-malarial HDAC inhibitor for Plasmodium (IC50: 31 nM) & human HDACs, with nanomolar potency across several subtypes.Formula:C21H24ClN5O2Color and Shape:SolidMolecular weight:413.9CRV431
CAS:CRV431 is a novel Pan-Cyclophilin Inhibitor, potently inhibiting all cyclophilin isoforms tested - A, B, D, and G (IC50 values ranged from 1-7 nM).Formula:C67H122N12O13Color and Shape:SolidMolecular weight:1303.76
